For the Inventor, By the Inventor

Enter assignee name

Brisbane, CA, United States of America

Unity Biotechnology, Inc.

USPTO Granted Patents = 41

% Expired Patents = 19.5

CIPO Patents = 1

EPO Patents = 7

Forward Citations = 132

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Nathaniel E David (25 out of 42 patents)

Remi-Martin Laberge (20 out of 24 patents)

Judith Campisi (17 out of 30 patents)

4. James L Kirkland (16 out of 21 patents)

5. Yi Zhu (16 out of 17 patents)

6. Tamar Tchkonia (16 out of 21 patents)

7. Marco Demaria (15 out of 19 patents)

8. Jan M A Van Deursen (13 out of 15 patents)

9. Alain Philippe Vasserot (12 out of 98 patents)

10. Darren J Baker (11 out of 13 patents)

11. Bennett G Childs (9 out of 9 patents)

12. Anne-Marie Beausoleil (8 out of 33 patents)

13. Ryan Hudson (8 out of 8 patents)

14. Albert Davalos (7 out of 7 patents)

15. Jamie Dananberg (4 out of 4 patents)

Core Competencies:

Senescent Cells

Bcl-xL Inhibitors

Ocular Diseases

Neurodegenerative Conditions

Pathological Angiogenesis

Peptide-Based Inhibitors

Gene Vector Therapy

Atherosclerosis Treatment

Chemical Entities

Drug Conjugates

Osteoarthritis Treatment

Immunogenic Compositions

41 patents: Sort by Forward Citations

1. 12285427 - Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor (2025-04-29),

2. 12221433 - Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2025-02-11),

3. 12195542 - Antibodies directed to Tie-2 and methods of use (2025-01-14),

4. 11980616 - Treating liver disease by selectively eliminating senescent cells (2024-05-14),

5. 11963957 - Treating cardiovascular disease by selectively eliminating senescent cells (2024-04-23),

6. 11951115 - Methods of treating retinal vasculopathies (2024-04-09),

7. 11865123 - Methods of inhibiting pathological angiogenesis (2024-01-09),

8. 11351167 - Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue (2022-06-07),

9. 11129838 - Methods of inhibiting pathological angiogenesis (2021-09-28),

10. 11111259 - Acylsulfonamide derivatives for treating senescence-associated diseases and disorders (2021-09-07),

11. 10981892 - Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2021-04-20),

12. 10745445 - Conjugates that are configured for targeted delivery of therapeutic compounds to senescent cells (2020-08-18),

13. 10745429 - Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2020-08-18),

14. 10738042 - Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2020-08-11),

15. 10717722 - Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer (2020-07-21),

Unity Biotechnology, Inc. is a biotechnology company focused on extending human healthspan, the period of time in which a person is healthy. Their mission is to treat the diseases of aging and help people live longer, healthier lives. They develop therapeutics using insights from human genetics and biology to remove senescent cells, which are known to contribute to age-related diseases. Unity Biotechnology aims to transform the lives of millions of aging individuals.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Unity Biotechnology, Inc.

41 Patents

#4 in Brisbane, CA

#1,982 in California

#8,415 in US

#16,645 in the World

Brisbane, CA, United States of America

Unity Biotechnology, Inc.

Forward Citations = 132

36 inventors:

Nathaniel E David (25 out of 42 patents)

Remi-Martin Laberge (20 out of 24 patents)

Judith Campisi (17 out of 30 patents)

4. James L Kirkland (16 out of 21 patents)

5. Yi Zhu (16 out of 17 patents)

Please report any incorrect information to [email protected]

Loading…